Chief Scientific Officer
Quantigen Biosciences
Doug is the Chief Scientific Officer (CSO) at Quantigen Biosciences, a role he has held since 2015. Before joining Quantigen, Doug worked as a Field Application Specialist at Thermo Fisher Scientific, where he was involved in the early development and support of pharmacogenetic testing, notably collaborating with institutions like Cincinnati Children's Hospital. Following his tenure at Thermo Fisher, he spent two years establishing and validating pharmacogenetics laboratories in the clinical sector.
Doug's expertise encompasses assay development, biomarker validation, and diagnostic regulatory filings across various methods and disease states. He has contributed to research on the performance of anterior nares and tongue swabs for nucleic acid detection, as evidenced by his publications on ResearchGate.
Throughout his career, Doug has emphasized the importance of technological advancements in pharmacogenomics, particularly in increasing throughput and improving the clinical applicability of genetic testing results. He advocates for rigorous validation processes to ensure accurate and consistent testing outcomes, especially concerning complex genes like CYP2D6.
Challenges in Precision Medicine Product Development
Wednesday, October 8, 2025
1:00 PM - 2:00 PM EST